If you look at last announcements and the hospitals recruited, they are second to none around the world and have agreed to work on the technology. Pancreatic cancer only has chemo as a standard of care. Agree past management have been lacking, but the new team, whilst lagging in dates, has got FDA, will get CE and pancreatic cancer treatments are needed badly.
Having spoken to the Company they are actively working with the hospitals now on recruitment. Have US, UK and Aus and should announce first patients in the next 2 months.
Previous management called it badly using BSI, but nearing the end of that now in any case. FDA read outs are 8 and 16 weeks, so would have thought this puppy will begin a sustainable rally from here and really hit its straps mid year to Sep. Probably to new highs. Extremely cheap for a company going to get data readouts, with better chemo than last trials and a proper protocol.
Agree has been extremely disappointing, but with data imminent, this period should be the making of this company.
OSL Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)